SG Americas Securities LLC Trims Holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK)

SG Americas Securities LLC lessened its position in Stoke Therapeutics, Inc. (NASDAQ:STOK - Free Report) by 78.3% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 14,917 shares of the company's stock after selling 53,684 shares during the quarter. SG Americas Securities LLC's holdings in Stoke Therapeutics were worth $183,000 as of its most recent filing with the SEC.

Several other institutional investors also recently modified their holdings of STOK. Healthcare of Ontario Pension Plan Trust Fund increased its holdings in Stoke Therapeutics by 426.1% in the second quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 1,387,200 shares of the company's stock valued at $18,741,000 after purchasing an additional 1,123,500 shares during the period. Lynx1 Capital Management LP boosted its position in Stoke Therapeutics by 40.3% during the second quarter. Lynx1 Capital Management LP now owns 5,185,191 shares of the company's stock valued at $70,052,000 after buying an additional 1,488,371 shares during the period. The Manufacturers Life Insurance Company raised its stake in Stoke Therapeutics by 16.7% in the second quarter. The Manufacturers Life Insurance Company now owns 13,964 shares of the company's stock worth $189,000 after buying an additional 1,994 shares in the last quarter. Millennium Management LLC grew its position in Stoke Therapeutics by 528.6% during the 2nd quarter. Millennium Management LLC now owns 289,067 shares of the company's stock valued at $3,905,000 after purchasing an additional 243,083 shares during the last quarter. Finally, Marshall Wace LLP increased its position in Stoke Therapeutics by 550.1% during the second quarter. Marshall Wace LLP now owns 1,161,037 shares of the company's stock valued at $15,686,000 after acquiring an additional 982,451 shares during the last quarter.

Insiders Place Their Bets

In other news, major shareholder Skorpios Trust sold 1,937,500 shares of the stock in a transaction on Thursday, September 19th. The stock was sold at an average price of $14.05, for a total value of $27,221,875.00. Following the completion of the transaction, the insider now directly owns 8,906,181 shares in the company, valued at approximately $125,131,843.05. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 11.30% of the company's stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on the company. Leerink Partners assumed coverage on Stoke Therapeutics in a report on Monday, October 14th. They set an "outperform" rating and a $18.00 price objective for the company. Needham & Company LLC restated a "buy" rating and issued a $22.00 price objective on shares of Stoke Therapeutics in a research note on Thursday, August 8th. Leerink Partnrs upgraded Stoke Therapeutics to a "strong-buy" rating in a report on Friday, October 11th. HC Wainwright restated a "buy" rating and issued a $35.00 target price on shares of Stoke Therapeutics in a research note on Wednesday, September 11th. Finally, Wedbush restated an "outperform" rating and set a $17.00 price objective on shares of Stoke Therapeutics in a research report on Thursday, July 11th. One investment analyst has rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat, the company presently has a consensus rating of "Buy" and a consensus target price of $20.83.

Stoke Therapeutics Trading Down 0.1 %

STOK traded down $0.01 on Thursday, hitting $12.05. The company had a trading volume of 149,421 shares, compared to its average volume of 778,817. Stoke Therapeutics, Inc. has a 1 year low of $3.35 and a 1 year high of $17.58. The company's fifty day moving average price is $13.58 and its 200 day moving average price is $13.70. The firm has a market cap of $634.43 million, a P/E ratio of -5.51 and a beta of 0.97.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last released its quarterly earnings results on Wednesday, August 7th. The company reported ($0.46) earnings per share for the quarter, topping analysts' consensus estimates of ($0.57) by $0.11. The business had revenue of $4.83 million during the quarter, compared to the consensus estimate of $3.33 million. Stoke Therapeutics had a negative net margin of 683.35% and a negative return on equity of 57.89%. On average, analysts predict that Stoke Therapeutics, Inc. will post -2.1 earnings per share for the current year.

Stoke Therapeutics Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.